© 2022 MJH Life Sciences™ and CGTLive™. All rights reserved.
All News
Bristol Myers to Fund Inflammatory Bowel Disease Treg Therapies
GentiBio will use their proprietary regulatory T cell platform to develop the engineered therapies against multiple targets.
Shannon L. Maude, MD, PhD, on Favorable Safety of Tisagenlecleucel in Pediatric B-ALL
The oncologist from Children's Hospital of Philadelphia discussed long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.
CGTLive’s Weekly Rewind – August 12, 2022
Review top news and interview highlights from the week ending August 12, 2022.